New funding to scale AI regulatory testing

The UK’s medicines regulator, the Medicines and Healthcare products Regulatory Agency, has secured £3.6 million in new funding to expand its pioneering AI regulatory sandbox programme, marking a significant step in the country’s ambition to become a global leader in digital health innovation.

The funding will support the next phase of the agency’s “AI Airlock” — a first-of-its-kind regulatory sandbox designed to test artificial intelligence technologies in a controlled environment before they are approved for use in clinical settings.

The expansion comes as demand grows for clearer, faster regulatory pathways for AI-powered medical devices, which are increasingly being adopted across the NHS and wider healthcare systems.

By scaling the sandbox, the MHRA aims to provide more developers with access to regulatory support, helping them navigate complex approval processes while ensuring patient safety remains paramount.

Building on early success of the AI Airlock

Launched in 2024, the AI Airlock was created to address the unique challenges posed by AI as a medical device, including issues such as algorithm transparency, bias, and continuous learning systems.

The pilot phase brought together regulators, clinicians, academics and technology companies to explore how emerging tools could be safely evaluated. Insights from real-world case studies have already informed early thinking on future regulatory frameworks.

The programme has since entered its second phase, running through 2026, with a new cohort of AI technologies undergoing testing.

These include tools for clinical note-taking, cancer diagnostics, eye disease detection and automated patient summaries, highlighting the breadth of AI applications now being explored in healthcare.

The additional £3.6 million investment is expected to expand participation, deepen evaluation capabilities and accelerate the translation of findings into formal regulatory guidance.

Supporting faster access to safe innovation

A central aim of the expanded sandbox is to reduce the time it takes for safe and effective AI technologies to reach patients.

Traditional regulatory pathways can take years to navigate, particularly for novel technologies that do not fit neatly within existing frameworks. Regulatory sandboxes offer a more flexible approach, allowing real-world testing under supervision while generating evidence for approval.

According to UK government analysis, such sandbox approaches can significantly shorten time-to-market for innovative technologies by enabling early engagement between developers and regulators.

For the NHS, this could translate into faster access to tools that improve diagnostics, streamline workflows and enhance patient outcomes.

However, the MHRA has emphasised that speed will not come at the expense of safety. The sandbox is designed to identify risks early, ensuring that only robust and trustworthy technologies progress to wider deployment.

Aligning with wider AI regulatory strategy

The expansion of the AI Airlock sits within a broader programme of regulatory reform aimed at adapting the UK’s medical device framework to the age of artificial intelligence.

The MHRA has established a National Commission on the Regulation of AI in Healthcare, bringing together experts from across clinical practice, technology and policy to develop a long-term strategy.

This work includes a national call for evidence and is expected to culminate in updated regulatory guidance in 2026, shaping how AI technologies are assessed, approved and monitored in the future.

The sandbox programme plays a critical role in this process, providing real-world insights into how AI systems perform in practice and where existing regulations may need to evolve.

Challenges around trust, bias and governance

Despite the promise of AI in healthcare, significant challenges remain.

Issues such as algorithmic bias, lack of transparency and the need for ongoing monitoring present complex regulatory questions. The AI Airlock has already explored areas including explainability, hallucinations in AI outputs and post-market surveillance.

Ensuring that AI systems are both effective and equitable is a key priority, particularly as these technologies begin to influence clinical decision-making.

There is also a growing need to define accountability, determining who is responsible when AI systems are used in patient care.

The sandbox approach allows these issues to be examined in a controlled setting, helping to build a more robust and adaptive regulatory framework.

Positioning the UK as a global leader

The expansion of the AI Airlock reinforces the UK’s ambition to lead internationally in the regulation of digital health technologies.

Regulatory sandboxes are increasingly being adopted worldwide, but the MHRA’s programme is among the most advanced in the healthcare sector.

By combining innovation with strong oversight, the UK aims to attract investment in health technology while maintaining high standards of patient safety.

For developers, the sandbox offers a clearer pathway to market. For clinicians and patients, it promises greater confidence in the safety and effectiveness of AI tools.

A pivotal moment for AI in healthcare

The £3.6 million funding boost represents a significant investment in the future of AI-driven healthcare.

As the NHS continues its digital transformation, the ability to safely integrate advanced technologies will be critical to improving efficiency and outcomes.

The expanded AI Airlock programme is expected to play a central role in this journey — bridging the gap between innovation and regulation, and ensuring that the benefits of AI can be realised without compromising trust or safety.